ADDITIONAL DRUGS FOR TREATMENT OF PNEUMOCYSTIS

治疗肺孢子虫病的其他药物

• 批准号: 3596116
• 负责人: RICHARD R TIDWELL
• 金额: $ 18.12万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 1987
• 资助国家: 美国
• 起止时间: 1987-07-10 至 1992-07-09
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3596116
• 关键词: AIDS; AIDS therapy; Pneumocystis; Pneumocystis pneumonia; antiprotozoal agents; disease /disorder model; drug design /synthesis /production; drug screening /evaluation; opportunistic infections; pentamidine; respiratory disorder chemotherapy

In the past two years pneumocystis pneumonia has become the major opportunistic disease in patients with acquired immunodeficiency syndrome (AIDS). The disease is rapidly progressive with a mortality rate over 40% despite treatment, whereas the mortality rate approaches 100% in untreated cases. Pentamidine is an effective chemotherapeutic agent but is highly toxic. Various combinations and analogs of pyrimethamine and sulfadiazine have been used with varying degrees of success. However, AIDS patients with pneumocystis pneumonia have not responded well to such treatment. The objective of this contract is to identify new drugs which have potential for use in the treatment of pneumocystis pneumonia in AIDS patients, utilizing animal models and/or in vitro techniques. Evaluation of such promising drugs in AIDS patients will then be carried out under a separate project.

近两年肺孢子菌肺炎已成为主要肺炎 获得性免疫缺陷综合征患者的机会性疾病 （艾滋病）。 该病进展迅速，死亡率超过40% 尽管接受治疗，但未经治疗的死亡率接近 100% 案例。 喷他脒是一种有效的化疗药物，但其副​​作用非常大。 有毒的。 乙胺嘧啶和磺胺嘧啶的各种组合和类似物 已被使用并取得了不同程度的成功。 然而，艾滋病患者 患有肺孢子虫肺炎的患者对此类治疗反应不佳。 该合同的目的是确定具有以下特征的新药： 用于治疗艾滋病肺孢子菌肺炎的潜力 患者，利用动物模型和/或体外技术。 评估 然后将在艾滋病患者中进行此类有前途的药物的研究 单独的项目。